38.26
Schlusskurs vom Vortag:
$40.37
Offen:
$39.61
24-Stunden-Volumen:
1.77M
Relative Volume:
1.54
Marktkapitalisierung:
$8.27B
Einnahmen:
$1.97B
Nettoeinkommen (Verlust:
$92.93M
KGV:
94.10
EPS:
0.4066
Netto-Cashflow:
$459.60M
1W Leistung:
-3.99%
1M Leistung:
+1.16%
6M Leistung:
-14.63%
1J Leistung:
-9.52%
Qiagen Nv Stock (QGEN) Company Profile
Firmenname
Qiagen Nv
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie QGEN mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
QGEN
Qiagen Nv
|
38.26 | 8.27B | 1.97B | 92.93M | 459.60M | 0.4066 |
![]()
TMO
Thermo Fisher Scientific Inc
|
437.91 | 165.21B | 42.88B | 6.34B | 7.27B | 16.53 |
![]()
DHR
Danaher Corp
|
181.77 | 130.05B | 23.88B | 3.90B | 5.30B | 5.28 |
![]()
IDXX
Idexx Laboratories Inc
|
393.73 | 31.91B | 3.90B | 887.87M | 798.08M | 10.67 |
![]()
A
Agilent Technologies Inc
|
103.00 | 29.38B | 6.53B | 1.26B | 1.31B | 4.35 |
![]()
IQV
Iqvia Holdings Inc
|
154.73 | 27.28B | 15.41B | 1.37B | 2.11B | 7.50 |
Qiagen Nv Stock (QGEN) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-02-19 | Herabstufung | Robert W. Baird | Outperform → Neutral |
2025-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
2024-12-10 | Hochstufung | Jefferies | Hold → Buy |
2024-10-17 | Herabstufung | HSBC Securities | Buy → Hold |
2024-06-27 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
2023-12-19 | Eingeleitet | Wells Fargo | Equal Weight |
2023-12-13 | Eingeleitet | Wolfe Research | Peer Perform |
2023-12-07 | Hochstufung | Goldman | Neutral → Buy |
2023-09-12 | Eingeleitet | Robert W. Baird | Outperform |
2023-05-23 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
2022-10-18 | Eingeleitet | Morgan Stanley | Equal-Weight |
2022-01-18 | Hochstufung | DZ Bank | Hold → Buy |
2021-10-15 | Fortgesetzt | Cowen | Market Perform |
2021-10-14 | Eingeleitet | Redburn | Buy |
2021-07-14 | Herabstufung | Kepler | Buy → Hold |
2021-06-03 | Eingeleitet | Goldman | Neutral |
2020-10-06 | Fortgesetzt | BofA Securities | Buy |
2020-09-28 | Hochstufung | Kepler | Hold → Buy |
2020-08-24 | Hochstufung | Citigroup | Neutral → Buy |
2020-08-20 | Fortgesetzt | JP Morgan | Overweight |
2020-08-17 | Hochstufung | Berenberg | Hold → Buy |
2020-08-14 | Hochstufung | Deutsche Bank | Hold → Buy |
2020-08-14 | Hochstufung | Exane BNP Paribas | Neutral → Outperform |
2020-03-04 | Herabstufung | Berenberg | Buy → Hold |
2020-01-08 | Eingeleitet | Wells Fargo | Equal Weight |
2020-01-07 | Eingeleitet | Citigroup | Neutral |
2019-12-26 | Fortgesetzt | BofA/Merrill | Underperform |
2019-11-15 | Eingeleitet | Stifel | Hold |
2019-11-14 | Hochstufung | Evercore ISI | In-line → Outperform |
2019-11-14 | Hochstufung | JP Morgan | Underweight → Overweight |
2019-11-14 | Hochstufung | Kepler | Reduce → Hold |
2019-10-17 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
2019-10-09 | Herabstufung | Kepler | Hold → Reduce |
2019-10-08 | Herabstufung | Barclays | Overweight → Equal Weight |
2019-10-08 | Herabstufung | Deutsche Bank | Buy → Hold |
2019-10-08 | Herabstufung | JP Morgan | Neutral → Underweight |
Alle ansehen
Qiagen Nv Aktie (QGEN) Neueste Nachrichten
Qiagen Announces Voting Rights Update with Bank of America - TipRanks
PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG - TradingView
Redburn cuts QIAGEN stock rating, lowers price target to EUR41 - Investing.com
Redburn-Atlantic Downgrades QIAGEN NV (QIA:GR) (QGEN) to Neutral - StreetInsider
Lab Automation Market Top PlayersF. Hoffmann-La Roche, Qiagen - openPR.com
Personalized Medicine Market Growth Trends 2025-2033: Transition to Customized Medical Care, Developments in Bioinformatics and Genomics, Growing Prevalence of Chronic Diseases - GlobeNewswire Inc.
QIAGEN Launches QIAprep& Plasmodium Kit to Strengthen Malaria Research and Surveillance Efforts - BioSpace
Qiagen introduces QIAprep Plasmodium kit to strengthen malaria research efforts - BioSpectrum Asia
Revolutionary Malaria Test Kit: QIAGEN's New Solution Detects 5 Species with Single-Parasite Sensitivity - Stock Titan
QIAGEN N.V. Files 2024 Annual Report with SEC - TipRanks
QIAGEN Announces Form 20-F Annual Report Filing for 2024 Results - DutchNews.nl
PTA-CMS: QIAGEN N.V.: Third country release according to Article 50 Para. 1, No. 2 of the WpHG [the German Securities Trading Act] - TradingView
QIAGEN Releases Full 2024 Annual Report: Access Complete Financial Data and Analysis - Stock Titan
Are Qiagen N.V.'s (NYSE:QGEN) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market? - Yahoo Finance
QIAGEN NV : Jefferies reiterates its Buy rating - Marketscreener.com
Qiagen N.V. (NYSE:QGEN) is a favorite amongst institutional investors who own 81% - simplywall.st
QIAGEN’s Eco-Friendlier Products Earn Prestigious ACT Label - Business Wire
Qiagen Manager Pledges Shares in Securities Lending Transaction - TipRanks
PTA-DD: QIAGEN N.V.: Managers' transactions announcement according to article 19 MAR - TradingView
QGEN Stock Might Rise Following Partnership With Genomics England - MSN
Is it Worth Retaining QIAGEN Stock in Your Portfolio Now? - Yahoo Finance
Digital Genome Market to Witness Remarkable Growth with QIAGEN, GenomeMe Inc., NanoString Technologies - openPR
The past three-year earnings decline for Qiagen (NYSE:QGEN) likely explains shareholders long-term losses - Yahoo Finance
Qiagen (QGEN) Down 6% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
FDA clears Qiagen’s QIAstat-Dx Gastrointestinal Panel 2 Mini B - Medical Device Network
Qiagen at TD Cowen Conference: Strategic Growth Plans Unveiled - Investing.com
Sector Update: Health Care Stocks Flat to Lower Premarket Thursday -March 06, 2025 at 09:14 am EST - Marketscreener.com
QIAGEN Gets US FDA Clearance for Second QIAstat-Dx Mini Gastrointestinal Panel -March 06, 2025 at 04:04 am EST - MarketScreener
How QIAGEN's Latest FDA Win Strengthens Its $4.6B Diagnostic Empire - Stock Titan
QIAGEN receives U.S. clearance for second QIAstat-Dx mini gastrointestinal panel, expanding U.S. syndromic testing portfolio - Silicon Canals
Market is not liking Qiagen's (NYSE:QGEN) earnings decline as stock retreats 4.7% this week - Simply Wall St
Analyzing Tevogen Bio (NASDAQ:TVGN) and Qiagen (NYSE:QGEN) - Defense World
QIAGEN Announces Managerial Transactions Involving Performance Stock Units - TipRanks
QIAGEN Announces Managerial Stock Transaction - TipRanks
Qiagen Announces Managerial Stock Unit Grant - TipRanks
Qiagen Announces Managerial Stock Transactions - TipRanks
Qiagen Announces Managerial Transaction Involving Restricted Stock Units - TipRanks
Qiagen N.V. (QGEN): Among the Cash-Rich Mid Cap Stocks to Buy Now - MSN
Relative Strength Alert For Qiagen - Nasdaq
10 Cash-Rich Mid Cap Stocks To Buy Now - Insider Monkey
BioMérieux: complaint lodged by German company Qiagen -March 03, 2025 at 05:57 am EST - Marketscreener.com
QIAGEN takes legal action to defend QuantiFERON intellectual property and protect innovations in latent tuberculosis testing - sharewise
Qiagen Files Patent Infringement Complaint in Germany Against bioMerieux -March 03, 2025 at 05:02 am EST - Marketscreener.com
How QIAGEN's Patent Lawsuit Against bioMérieux Could Reshape the TB Testing Market - Stock Titan
What is Zacks Research’s Estimate for Qiagen Q1 Earnings? - Defense World
QIAGEN Files Patent Complaint Against BioMérieux To Protect QuantiFERON Technology - Nasdaq
Qiagen Takes Legal Action To Defend Quantiferon Intellectual Property -March 03, 2025 at 01:04 am EST - Marketscreener.com
Zacks Research Issues Negative Estimate for Qiagen Earnings - Defense World
Zacks Research Forecasts Qiagen's Q4 Earnings (NYSE:QGEN) - MarketBeat
Qiagen (NYSE:QGEN) Reaches New 12-Month LowWhat's Next? - MarketBeat
Qiagen (NYSE:QGEN) Receives Average Rating of “Hold” from Brokerages - Defense World
Finanzdaten der Qiagen Nv-Aktie (QGEN)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):